CDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer: Current Practice and Knowledge.
CDK4/6 inhibitors
hormone receptor-positive breast cancer
metastatic breast cancer
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
01 Sep 2020
01 Sep 2020
Historique:
received:
08
07
2020
revised:
10
08
2020
accepted:
14
08
2020
entrez:
5
9
2020
pubmed:
5
9
2020
medline:
5
9
2020
Statut:
epublish
Résumé
Treatment paradigms in advanced hormone receptor (HR)-positive breast cancer were substantially transformed with cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) approval. The addition of these drugs to endocrine treatment profoundly improved progression-free and overall survival. Additionally, other important endpoints, such as the response rate, time to chemotherapy, and a delay in quality of life deterioration, were positively impacted by CDK4/6 inhibitors' addition to the treatment of advanced HR-positive breast cancer. This review article will summarize current knowledge on CDK4/6 inhibitors in clinical practice for advanced HR-positive metastatic breast cancer, as well as describe recent efforts to more precisely characterize mechanisms of sensitivity and resistance to these drugs, both on the molecular and clinical characterization level.
Identifiants
pubmed: 32882980
pii: cancers12092480
doi: 10.3390/cancers12092480
pmc: PMC7563142
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Cancer Cell. 2018 Dec 10;34(6):893-905.e8
pubmed: 30537512
N Engl J Med. 2013 Mar 28;368(13):1199-209
pubmed: 23484797
J Cell Biochem. 2006 Feb 1;97(2):261-74
pubmed: 16267837
Clin Cancer Res. 2015 Nov 1;21(21):4947-59
pubmed: 25810375
Clin Cancer Res. 2017 Sep 1;23(17):5218-5224
pubmed: 28533223
Cancer Res. 2001 Feb 15;61(4):1659-65
pubmed: 11245480
Trends Cancer. 2017 Jan;3(1):39-55
pubmed: 28303264
Nature. 2010 Dec 23;468(7327):1074-9
pubmed: 21179163
Nat Commun. 2018 Mar 1;9(1):896
pubmed: 29497091
Ann Transl Med. 2018 Jun;6(11):233
pubmed: 30023396
J Clin Oncol. 2018 Aug 20;36(24):2465-2472
pubmed: 29860922
J Clin Oncol. 2017 Sep 1;35(25):2875-2884
pubmed: 28580882
Expert Rev Anticancer Ther. 2017 Sep;17(9):851-856
pubmed: 28699811
Oncogene. 2017 Apr 20;36(16):2255-2264
pubmed: 27748766
Sci Transl Med. 2015 Aug 26;7(302):302ra133
pubmed: 26311728
Drug Metab Dispos. 2015 Sep;43(9):1360-71
pubmed: 26149830
N Engl J Med. 2016 Nov 3;375(18):1738-1748
pubmed: 27717303
J Clin Oncol. 2017 Nov 10;35(32):3638-3646
pubmed: 28968163
Crit Rev Oncol Hematol. 2012 Dec;84(3):301-13
pubmed: 22710198
Breast Cancer Res. 2009;11(5):R77
pubmed: 19874578
N Engl J Med. 2018 Nov 15;379(20):1926-1936
pubmed: 30345905
Cell. 1999 Sep 17;98(6):859-69
pubmed: 10499802
Ann Oncol. 2018 Mar 1;29(3):669-680
pubmed: 29342248
Nat Genet. 2013 Dec;45(12):1446-51
pubmed: 24185510
J Clin Oncol. 2016 Sep 1;34(25):2961-8
pubmed: 27269946
Lancet Oncol. 2018 Jul;19(7):904-915
pubmed: 29804902
Oncotarget. 2016 Aug 19;8(40):66901-66911
pubmed: 28978004
N Engl J Med. 2019 Jul 25;381(4):307-316
pubmed: 31166679
Nat Rev Drug Discov. 2015 Feb;14(2):130-46
pubmed: 25633797
Nat Commun. 2019 Mar 26;10(1):1373
pubmed: 30914635
Lancet Oncol. 2015 Jan;16(1):25-35
pubmed: 25524798
PLoS One. 2020 Jun 4;15(6):e0233571
pubmed: 32497134
Mol Cell Biol. 1995 May;15(5):2672-81
pubmed: 7739547
Sci Transl Med. 2015 Nov 11;7(313):313ra182
pubmed: 26560360
J Clin Oncol. 2018 Jun 1;36(16):1631-1641
pubmed: 29504847
Breast Cancer Res. 2008;10(1):R20
pubmed: 18307763
Breast Cancer Res Treat. 2019 Apr;174(3):719-729
pubmed: 30632023
Cancer Cell. 2017 Dec 11;32(6):761-776.e6
pubmed: 29232554
Lancet Oncol. 2016 Apr;17(4):425-439
pubmed: 26947331
Mol Cell Biol. 1995 May;15(5):2682-8
pubmed: 7739548
Cell Cycle. 2012 Jul 15;11(14):2756-61
pubmed: 22767154
N Engl J Med. 2016 Nov 17;375(20):1925-1936
pubmed: 27959613
Lancet Oncol. 2020 Jun;21(6):763-775
pubmed: 32353342
Nat Rev Clin Oncol. 2016 Jul;13(7):417-30
pubmed: 27030077
Ann Oncol. 2009 May;20(5):803-5
pubmed: 19403934
JAMA Oncol. 2019 Sep 29;:
pubmed: 31563959
Nat Rev Cancer. 2011 Jul 07;11(8):558-72
pubmed: 21734724